Associate Professor of Medicine
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
I was fortunate to have excellent internal medicine training at Bellevue,, and hematology/oncology training at the University of California San Diego. Following this I went on active duty in the US Air Force and was stationed in San Antonio, Tx. I then moved to the UT Health Science Center in San Antionio
and then arrived at my current location in 2004 at the University of Wisconsin. My career goals have been to further our understanding and treatment of multiple myeloma and the role of transplantation in treating this disease. Twenty five years ago, myeloma was considered by many to be an untreatable cancer, with two forms of therapy, namely radiation and oral melphalan and prednisone. Over the past twenty years, insight has been gained into the complex mechanisms that lead to myeloma propagation. These observations have directly led to new treatments, which have created impressive gains in myeloma control and survival. However myeloma remains an incurable illness, characterized by increasingly refractory relapses. While we have many active therapies for newly diagnosed myeloma, the therapeutic landscape for relapsed, refractory myeloma patients is complex. Some patients respond easily and re-enter remission. Others display increasingly intractable disease. The mechanisms that lead to drug resistance are not completely understood. I am thrilled that so many investigators are working tirelessly around the world to improve myeloma treatments and outcomes.
Disclosure information not submitted.
Friday, March 25, 2022
1:50 PM – 2:55 PM
Friday, March 25, 2022
2:15 PM – 2:35 PM
Friday, March 25, 2022
2:35 PM – 2:55 PM
Friday, June 24, 2022
10:55 AM – 12:00 PM
Friday, June 24, 2022
11:20 AM – 11:40 AM
Friday, June 24, 2022
11:40 AM – 12:00 PM
Friday, June 24, 2022
3:05 PM – 4:10 PM
Friday, June 24, 2022
3:30 PM – 3:50 PM
Friday, June 24, 2022
3:50 PM – 4:10 PM